Compare CMPX & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPX | MTLS |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.8M | 387.8M |
| IPO Year | 2020 | 2014 |
| Metric | CMPX | MTLS |
|---|---|---|
| Price | $2.15 | $6.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $14.57 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 53.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.38 |
| Revenue Next Year | $934.41 | $6.45 |
| P/E Ratio | ★ N/A | $61.39 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.61 | $4.78 |
| 52 Week High | $6.88 | $7.50 |
| Indicator | CMPX | MTLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 55.25 |
| Support Level | $1.88 | $6.36 |
| Resistance Level | $2.02 | $6.89 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 37.33 | 87.50 |
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.